Multiple myeloma is a blood cancer that can leave bones fragile and prone to breaking, especially in the spine. This can lead to debilitating pain and, in rare cases, pressure on the spinal cord. A fresh look at past clinical trials offers some clarity on whether bone-modifying drugs can help shield patients from these complications. The analysis found that a class of drugs called bisphosphonates, particularly one named zoledronate, was linked to a lower risk of vertebral fractures compared to getting no treatment or a placebo. This is encouraging news for managing a common and painful problem. But the picture isn't complete. The review couldn't draw a firm conclusion about whether these drugs prevent spinal cord compression, a more severe complication, because there wasn't enough evidence. It's also important to note that the studies didn't report on how much these prevented fractures actually improved patients' daily lives or reduced pain. Furthermore, the analysis didn't include any studies on another bone drug, denosumab, so its role remains unknown. The findings come from controlled trial settings, and researchers caution that more evidence is needed to understand their full impact in everyday clinical practice.
Bisphosphonates reduce vertebral fracture risk in multiple myeloma, spinal cord compression effect unclearCan bone drugs protect the spine in multiple myeloma? A new review weighs in
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider bisphosphonates for vertebral fracture risk reduction in myeloma, but recognize spinal cord compression effect is unclear.
This systematic review and meta-analysis examined 11 randomized trials evaluating bone-modifying agents (bisphosphonates and denosumab) versus no treatment or placebo for preventing vertebral complications in adults with multiple myeloma. Lower-potency bisphosphonates were associated with a pooled relative risk (RR) of 0.72 (95% CI: 0.61-0.85, p=.0001) for vertebral fractures, while zoledronate showed a stronger association with an RR of 0.36 (95% CI: 0.16-0.77, p=.009). The meta-analysis for spinal cord compression was inconclusive due to limited evidence.
No studies investigating denosumab met inclusion criteria, so its effects remain unassessed. Safety and tolerability data were not reported in the review. The analysis used GRADE methodology to evaluate evidence certainty, though the specific ratings were not provided.
Key limitations include that none of the included studies reported the clinical significance of preventing these vertebral fractures, and the findings are derived from trial conditions. The conclusion notes that additional evidence is necessary to understand real-world clinical impact. For practice, bisphosphonates show association with reduced vertebral fracture risk in this population, but clinicians should recognize the unclear effect on spinal cord compression and the absence of denosumab data.
What this means for you:
Bone drugs can lower spine fracture risk in myeloma, but protection against spinal cord compression is unclear. More on Multiple Myeloma
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma.
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates
New osteoporosis treatments target bone-eating cells more safely
This narrative review examines emerging therapeutic strategies that target osteoclast fusion and polarization, including DC-STAMP/OC-STAMP n…
Future osteoporosis drugs may work by blocking the fusion of bone-destroying cells, offering a safer alternative to current treatments.
VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7
Current risk tools for blood clots in multiple myeloma patients do not work well enough for doctors to trust
This systematic review and meta-analysis of 14 studies evaluated VTE risk prediction models in multiple myeloma. Pooled VTE incidence was 7.…
A review of fourteen studies found that existing models fail to accurately predict blood clots in multiple myeloma patients. The tools used …
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
View Original Abstract ↓
BACKGROUND CONTEXT: Bone disease in patients with multiple myeloma (MM) is associated with vertebral complications, which include vertebral fractures and spinal cord compression (SCC). Bone-modifying agents (BMAs), namely bisphosphonates and denosumab, are recommended to reduce skeletal-related events in MM, yet their efficacy in preventing vertebral fractures and SCC remains unclear.
PURPOSE: To determine the efficacy of bone-modifying agents (BMAs) in reducing the risk for vertebral fractures and SCC in adults with MM.
STUDY DESIGN: Systematic review and meta-analysis following PRISMA guidelines.
METHODS: A systematic search of PubMed, Embase, and Web of Science databases was performed on July 11, 2024. Risk of bias, reporting bias, and evidence certainty were evaluated using the RoB 2 tool, funnel plot and Egger's test, and the GRADE approach, respectively. Relevant data were extracted and pooled for pairwise and network meta-analysis.
RESULTS: After removing duplicates, 1,354 studies were screened, 108 full-text studies were reviewed for inclusion, and 11 randomized trials were included in the analysis. Compared to no treatment or placebo, lower-potency bisphosphonates were associated with a reduction in the risk for vertebral fractures, with a pooled RR of 0.72 (95% CI: 0.61-0.85, p=.0001), suggesting a 28% reduction in risk. Zoledronate was the most efficacious bisphosphonate in the network meta-analysis, with a 64% reduction in vertebral fracture risk compared to no treatment or placebo (RR=0.36, 95% CI: 0.16-0.77, p=.009). None of the included studies reported the clinical significance of these vertebral complications, and no studies that investigated denosumab met inclusion criteria. Meta-analysis for the SCC outcome was inconclusive due to limited evidence.
CONCLUSIONS: The body of literature indicates that bisphosphonates, particularly zoledronate, significantly reduce the risk for vertebral fractures in patients with MM, at least in trial conditions. Additional evidence is necessary to evaluate the real-world clinical impact of these findings, clarify the effects on risk for SCC, and investigate denosumab.
Reverse Shoulder Arthroplasty Improves Forward Flexion Over ORIF in Elderly Fracture Patients
Reverse shoulder replacement beats plate surgery for arm lifting
Related in Orthopedics & Sports Medicine
Mind-body training improves upper-limb function after stroke, optimal dose near 33.5 hours
Mind body training improves arm function for stroke survivors
This meta-analysis of 16 RCTs (769 participants) found that mind-body training (MBT), including Tai Chi, significantly improves upper-limb f…
New data shows that mind body exercises like Tai Chi can significantly improve arm movement and function for people recovering from a stroke…
Focused ultrasound ablation surgery monotherapy improves dysmenorrhea remission and menorrhagia scores in patients with adenomyosis
Focused Ultrasound Surgery Shows Promise for Adenomyosis Treatment
This systematic review and meta-analysis of 27 studies involving 13,307 patients found that focused ultrasound ablation surgery (FUAS) signi…
A large review of over 13,000 patients suggests focused ultrasound surgery can effectively reduce period pain and heavy bleeding in adenomyo…
Unilateral Extrapedicular and Bilateral Transpedicular Approaches in Percutaneous Kyphoplasty
One-sided approach for spine fracture repair may be safer
A meta-analysis suggests that unilateral extrapedicular approaches provide comparable clinical outcomes to bilateral transpedicular methods …
A new analysis suggests a one-sided needle approach for spine fracture repair cuts radiation and cement leakage while working just as well.
AI-assisted instruction provides diverse tools for undergraduate medical education clinical skills training
AI Tools are Growing in Medical Student Clinical Training
This scoping review of 39 studies identifies various AI innovations in undergraduate medical education, including LLM-based virtual patients…
New research identifies how artificial intelligence tools like virtual patients and robotic simulations are being used to train medical stud…
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …